Preoperative serum vascular endothelial growth factor correlated to three dimensional power Doppler indices in ovarian masses

DOI: 10.4236/ojog.2014.43021   PDF   HTML     3,688 Downloads   5,212 Views   Citations


Objective: To assess the preoperative serum levels of vascular endothelial growth factor (VEGF) in ovarian masses compared to normal controls and to find a correlation between VEGF and Doppler indices in ovarian masses. Methods: The study was conducted from December 2009 to September 2012 in the oncology and ultrasound units in department of obstetrics and gynecology, Ain Shams University on 150 patients with ovarian masses. During preoperative workup, serum Ca-125 levels and serum VEGF levels were obtained. Ultrasonographic examination included two and three dimensional power Doppler ultrasound (3DPD). Laparotomic approaches were undertaken to obtain the final pathologic results. VEGF was measured in one hundred normal cases as controls. Results: Final ovarian pathology revealed seventy three malignant ovarian masses and seventy seven were benign. Serum Ca-125 levels in malignant cases were higher compared to those in benign cases (p < 0.001). Preoperative serum VEGF revealed higher levels in malignant ovarian masses than benign conditions and normal controls (p < 0.001). Three dimensional power Doppler indices, vascularization index (VI), flow index (FI) and vascularization flow index (VFI), correlated positively with serum VEGF levels. Conclusion: Preoperative serum VEGF revealed higher levels in malignant ovarian masses than benign conditions and normal controls. These levels positively correlated with the Doppler vascular indices of the masses.

Share and Cite:

AbouSeeda, M. , Mansour, G. and Ez-Elarab, S. (2014) Preoperative serum vascular endothelial growth factor correlated to three dimensional power Doppler indices in ovarian masses. Open Journal of Obstetrics and Gynecology, 4, 112-119. doi: 10.4236/ojog.2014.43021.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Oriel, K.A., Hartenbach, E.M. and Remington, P.L. (1999) Trends in United States ovarian cancer mortality, 1979-1995. Obstetrics & Gynecology, 93, 30-33. (98)00397-4
[2] Duncan, T.J., Al-Attar, A., Rolland, P., Scott, I.V., Deen, S., Liu, D.T., Spendlove, I. and Durrant, L.G. (2008) Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clinical Cancer Research, 14, 3030-3035. CCR-07-1888
[3] Laban, M., Metawee, H., Elyan, A., Kamal, M., Kamel, M. and Mansour, G. (2007) Three-dimensional ultrasound and three-dimensional power Doppler in the assessment of ovarian tumors. International Journal of Gynecology & Obstetrics, 99, 201-205.
[4] Mansour, G.M., El-Lamie, I.K., El-Sayed, H.M., Ibrahim, A.M., Laban, M., Abou-Louz, S.K., Abd Allah, M.Y., El-Mahallawi, M.N., El-Lamie, K.I. and Gad-Allah, M. (2009) Adnexal mass vascularity assessed by 3-dimensional power Doppler: Does it add to the risk of malignancy index in prediction of ovarian malignancy?: Four hundred-case study. International Journal of Gynecological Cancer, 19, 867-872.
[5] Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J. and Cronin, K.A., Eds. (2013) SEER Cancer Statistics Review, National Cancer Institute, Bethesda. http://seer.cancer. gov/csr/1975_2010/
[6] Manjunath, A.P., Pratapkumar, A.P. and Sujatha, K. (2001) Comparison of three risk-of-malignancy indices in evaluation of pelvic masses. Gynecologic Oncology, 81, 225-229. 1006/gyno.2001.6122
[7] Yuen, P.M., Yu, K.M. and Yip, S.K. (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. American Journal of Obstetrics & Gynecology, 177, 109-114.
[8] Benedet, J.L., Hacker, N.F. and Ngan, H.Y.S. (2000) Staging classifications and clinical practice guidelines of gynaecologic cancers. International Journal of Gynecology & Obstetrics, 70, 207-312.
[9] Jacobs, I., Oram, D., Fairbanks, J., et al. (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology, 97, 922-929. tb02448.x
[10] Davies, A.P., Jacobs, I., Woolas, R., Fish, A. and Oram, D. (1993) The adnexal mass: Benign or malignant? Evaluation of a risk of malignancy index. British Journal of Obstetrics and Gynaecology, 100, 927-931.
[11] Tingulstad, S., Hagen, B. and Skjeldestad, F.E. (1996) Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. British Journal of Obstetrics and Gynaecology, 103, 826-831. j.1471-0528.1996.tb09882.x
[12] Andersen, E.S., Knudsen, A., Rix, P., et al. (2003) Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecologic Oncology, 90, 109-112.
[13] Hu, L., Hofmann, J., Holash, J., Yancopoulos, G.D., Sood, A.K. and Jaffe, R.B. (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clinical Cancer Research, 11, 6966-6971.
[14] Kidron, D., Bernheim, J., Aviram, R., Cohen, I., Fishman, A., Beyth, Y. and Tepper, R. (1999) Resistance to blood flow in ovarian tumors: Correlation between resistance index and histological pattern of vascularization. Ultrasound in Obstetrics & Gynecology, 13, 425-430. 1469-0705.1999.13060425.x
[15] Robati, M., Ghaderi, A., Mehraban, M., Shafizad, A., Nasrolahi, H. and Mohammad, M. (2013) Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Archives of Gynecology and Obstetrics, 288, 859-865.
[16] Cooper, B.C., Ritchie, J.M., Broghammer, C.L., Coffin, J., Sorosky, J.I., Buller, R.E., Hendrix, M.J. and Sood, A.K. (2002) Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clinical Cancer Research, 8, 3193-3197.
[17] Harlozinska, A., Sedlaczek, P., Kulpa, J., Grybos, M., Wójcik, E., Van Dalen, A. and Einarsson, R. (2004) Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Research, 24, 1149-1157.
[18] Demirkiran, F., Kumbak, B., Bese, T., Arvas, M., Benian, A., Aydin, S., Uzun, H., Sanioglu, C., Aydinli, K. and K?sebay, D. (2003) Vascular endothelial growth factor in adnexal masses. International Journal of Gynecology & Obstetrics, 83, 53-58.
[19] Tanir, H.M., Ozalp, S., Yalcin, O.T., Colak, O., Akcay, A. and Senses, T. (2003) Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. European Journal of Gynaecological Oncology, 24, 271-274.
[20] Lutgendorf, S.K., Johnsen, E.L., Cooper, B., Anderson, B., Sorosky, J.I., Buller, R.E. and Sood, A.K. (2002) Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95, 808-815.
[21] Obermair, A., Tempfer, C., Hefler, L., Preyer, O., Kaider, A., Zeillinger, R., Leodolter, S. and Kainz, C. (1998) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. British Journal of Cancer, 77, 1870-1874.
[22] Mu, J., Abe, Y., Tsutsui, T., Yamamoto, N., Tai, X.G., Niwa, O., Tsujimura, T., Sato, B., Terano, H., Fujiwara, H. and Hamaoka, T. (1996) Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Japanese Journal of Cancer Research, 87, 963-971.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.